FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3113602892> ?p ?o ?g. }

• W3113602892 endingPage "159" @default.
• W3113602892 startingPage "149" @default.
• W3113602892 abstract "Viloxazine extended-release (viloxazine ER, SPN-812) is a novel non-stimulant with activity at serotonin receptors and the norepinephrine transporter, which is under investigation as a potential treatment for attention-deficit/hyperactivity disorder. Given the potential for viloxazine ER to be coadministered with other pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine ER + methylphenidate versus viloxazine ER or methylphenidate alone.In this single-center, crossover, open-label trial, healthy adult participants received oral administration of 700 mg viloxazine ER alone, 36 mg methylphenidate alone, and combination viloxazine ER (700 mg) + methylphenidate (36 mg), with blood samples collected over 4 days post-administration. The active drug in viloxazine ER (viloxazine) and methylphenidate was measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events (AEs), vital signs, echocardiograms, and clinical laboratory evaluations.Of 36 healthy adults who were enrolled, 34 completed the trial. The geometric least squares mean ratios are reported as [combination/single drug (90% confidence intervals)]. For viloxazine ER, maximum measured plasma concentration (Cmax) = 100.98% (96.21-105.99), area under the concentration-time curve from time zero to the last measurable time (AUCt) = 98.62% (96.21-101.08), and area under the concentration-time curve from time zero to infinity (AUC∞) = 98.96% (96.55-101.44). For methylphenidate, Cmax = 103.55% (97.42-110.07), AUCt = 106.67% (101.01-112.64), and AUC∞ = 106.61% (100.99-112.54). All reported AEs were mild in severity.Coadministration of viloxazine ER and methylphenidate did not impact the pharmacokinetics of viloxazine or methylphenidate relative to administration of either drug alone. The combination appeared to be safe and well tolerated." @default.
• W3113602892 created "2021-01-05" @default.
• W3113602892 creator A5009610620 @default.
• W3113602892 creator A5029826453 @default.
• W3113602892 creator A5034593787 @default.
• W3113602892 creator A5036952053 @default.
• W3113602892 creator A5068715811 @default.
• W3113602892 creator A5072097629 @default.
• W3113602892 creator A5072640106 @default.
• W3113602892 creator A5075556362 @default.
• W3113602892 date "2020-12-23" @default.
• W3113602892 modified "2023-10-17" @default.
• W3113602892 title "Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults" @default.
• W3113602892 cites W1502167289 @default.
• W3113602892 cites W1684863429 @default.
• W3113602892 cites W1908107875 @default.
• W3113602892 cites W1970031540 @default.
• W3113602892 cites W1975946728 @default.
• W3113602892 cites W1976641170 @default.
• W3113602892 cites W1981468760 @default.
• W3113602892 cites W1993767643 @default.
• W3113602892 cites W1999039388 @default.
• W3113602892 cites W2004892604 @default.
• W3113602892 cites W2006058627 @default.
• W3113602892 cites W2016496786 @default.
• W3113602892 cites W2018902832 @default.
• W3113602892 cites W2022821210 @default.
• W3113602892 cites W2026671901 @default.
• W3113602892 cites W2037420498 @default.
• W3113602892 cites W2048364865 @default.
• W3113602892 cites W2071397484 @default.
• W3113602892 cites W2117104588 @default.
• W3113602892 cites W2128931976 @default.
• W3113602892 cites W2137263250 @default.
• W3113602892 cites W2171074660 @default.
• W3113602892 cites W2489026659 @default.
• W3113602892 cites W2587631464 @default.
• W3113602892 cites W2735057791 @default.
• W3113602892 cites W2789958560 @default.
• W3113602892 cites W2933452394 @default.
• W3113602892 cites W3025751746 @default.
• W3113602892 cites W3045331755 @default.
• W3113602892 cites W3080466884 @default.
• W3113602892 cites W3092495109 @default.
• W3113602892 cites W4236486344 @default.
• W3113602892 doi "https://doi.org/10.1007/s40261-020-00992-6" @default.
• W3113602892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7886742" @default.
• W3113602892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33368026" @default.
• W3113602892 hasPublicationYear "2020" @default.
• W3113602892 type Work @default.
• W3113602892 sameAs 3113602892 @default.
• W3113602892 citedByCount "11" @default.
• W3113602892 countsByYear W31136028922021 @default.
• W3113602892 countsByYear W31136028922022 @default.
• W3113602892 countsByYear W31136028922023 @default.
• W3113602892 crossrefType "journal-article" @default.
• W3113602892 hasAuthorship W3113602892A5009610620 @default.
• W3113602892 hasAuthorship W3113602892A5029826453 @default.
• W3113602892 hasAuthorship W3113602892A5034593787 @default.
• W3113602892 hasAuthorship W3113602892A5036952053 @default.
• W3113602892 hasAuthorship W3113602892A5068715811 @default.
• W3113602892 hasAuthorship W3113602892A5072097629 @default.
• W3113602892 hasAuthorship W3113602892A5072640106 @default.
• W3113602892 hasAuthorship W3113602892A5075556362 @default.
• W3113602892 hasBestOaLocation W31136028921 @default.
• W3113602892 hasConcept C112705442 @default.
• W3113602892 hasConcept C118552586 @default.
• W3113602892 hasConcept C142724271 @default.
• W3113602892 hasConcept C197934379 @default.
• W3113602892 hasConcept C204787440 @default.
• W3113602892 hasConcept C22979827 @default.
• W3113602892 hasConcept C27081682 @default.
• W3113602892 hasConcept C2777112843 @default.
• W3113602892 hasConcept C2780783007 @default.
• W3113602892 hasConcept C71924100 @default.
• W3113602892 hasConcept C87813604 @default.
• W3113602892 hasConcept C98274493 @default.
• W3113602892 hasConceptScore W3113602892C112705442 @default.
• W3113602892 hasConceptScore W3113602892C118552586 @default.
• W3113602892 hasConceptScore W3113602892C142724271 @default.
• W3113602892 hasConceptScore W3113602892C197934379 @default.
• W3113602892 hasConceptScore W3113602892C204787440 @default.
• W3113602892 hasConceptScore W3113602892C22979827 @default.
• W3113602892 hasConceptScore W3113602892C27081682 @default.
• W3113602892 hasConceptScore W3113602892C2777112843 @default.
• W3113602892 hasConceptScore W3113602892C2780783007 @default.
• W3113602892 hasConceptScore W3113602892C71924100 @default.
• W3113602892 hasConceptScore W3113602892C87813604 @default.
• W3113602892 hasConceptScore W3113602892C98274493 @default.
• W3113602892 hasIssue "2" @default.
• W3113602892 hasLocation W31136028921 @default.
• W3113602892 hasLocation W31136028922 @default.
• W3113602892 hasLocation W31136028923 @default.
• W3113602892 hasOpenAccess W3113602892 @default.
• W3113602892 hasPrimaryLocation W31136028921 @default.
• W3113602892 hasRelatedWork W1971830765 @default.
• W3113602892 hasRelatedWork W2033685750 @default.
• W3113602892 hasRelatedWork W2053536280 @default.

• next